Recent 8-K filings for AMPH

• June 3, 2026, 4:15 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×4

  Amphastar shareholders elect three directors, ratify EY, approve say-on-pay

  All three Class I nominees elected: Gaugh 35.2M for, Peters 23.6M for, Liawatidewi 23.2M for.

• May 7, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  Amphastar Q1 2026 GAAP net income drops 75% to $6.4M; adjusted EPS falls to $0.42

  Net revenues flat at $171.2M vs $170.5M YoY.

• March 16, 2026, 7:59 PM ET other material materiality 0.45 positive item 8.01

  Amphastar Board authorizes $50M increase to share buyback program

  Board authorized $50M increase to buyback program on March 12, 2026.

• March 6, 2026, 6:59 PM ET other material materiality 0.25 neutral item 1.01item 9.01 ◈ Material Agreements ×2

  Amphastar enters supply agreement with related party Letop, amends contract with Hanxin

  Supply agreement with Nanjing Letop (Henry Zhang, son of CEO); no minimum purchase, 5-year term.

• March 6, 2026, 6:59 PM ET other material materiality 0.55 neutral item 5.02item 9.01

  Amphastar enters employment agreements with two executives; base salaries $525,800 and $590,000

  Jacob Liawatidewi (EVP of Corp Admin) base salary $525,800, target bonus 55%.

• February 26, 2026, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Amphastar Q4 revenue $183.1M, down 1.8% YoY; GAAP EPS $0.51 vs $0.74

  Full year 2025 net revenue $719.9M, down 1.6% YoY from $732.0M.

• January 12, 2026, 6:59 PM ET other material materiality 0.70 positive item 1.01item 7.01item 9.01 ◈ Material Agreements ×3

  Amphastar Licenses Synthetic Corticotropin (AMP-110) from Hanxin in Exclusive US/Canada Deal

  Amphastar gained exclusive rights to develop and commercialize AMP-110 (synthetic ACTH) in the US and Canada from Nanjing Hanxin.

• November 6, 2025, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Amphastar Q3 net income drops 57% YoY to $17.4M; adjusted EPS $0.93 vs $0.96

  Net revenues of $191.8M, flat YoY vs $191.2M.

• October 24, 2025, 7:59 PM ET other material materiality 0.55 neutral item 1.01

  Amphastar enters exclusive BAQSIMI distribution deal for Greater China with related party

  Exclusive distributor Chengong will market BAQSIMI in Mainland China, Taiwan, Hong Kong, Macau.

• September 18, 2025, 7:59 PM ET other material materiality 0.55 neutral item 1.01

  Amphastar enters $2.8M R&D agreement with related-party Hanxin for AMP-107 cell banks

  Agreement with Nanjing Hanxin to develop Recombinant Peptide Research Cell Banks (RCBs) for product candidate AMP-107.

• August 12, 2025, 7:59 PM ET M&A materiality 0.75 positive item 1.01item 7.01item 9.01

  Amphastar licenses three novel peptides from Anji for up to $453M total

  Exclusive license for three proprietary peptides targeting oncology and ophthalmology in U.S. and Canada.

• August 7, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Amphastar Q2 2025 revenue $174.4M, GAAP EPS $0.64; BAQSIMI sales up 21%

  Net revenues $174.4M vs $182.4M YoY; GAAP net income $31.0M ($0.64 diluted EPS).

• July 21, 2025, 7:59 PM ET leadership materiality 0.30 neutral item 5.02

  Amphastar appoints David Gaugh as Class I director; board size increased to 11

  Board increased authorized directors from 10 to 11 and appointed David Gaugh effective July 18, 2025.

• June 4, 2025, 7:59 PM ET other materiality 0.25 neutral item 5.03item 5.07item 9.01 ◈ Governance Changes ×3

  Stockholders approve charter amendments for officer exculpation and forum selection removal at annual meeting

  Elected three Class III directors: Jack Y. Zhang, Richard Prins, Diane G. Gerst (each with majority support).

• May 7, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Amphastar Q1 2025 GAAP net income $25.3M ($0.51 EPS); adjusted EPS $0.74

  Net revenues $170.5M, down from $171.8M in Q1 2024.

• February 27, 2025, 6:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01

  Amphastar Q4 net revenue $186.5M, adj EPS $0.92; FY $732M, adj EPS $3.86

  Q4 net revenue $186.5M, up 4.7% YoY; GAAP net income $38.0M ($0.74 per share).

• November 6, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Amphastar Q3 2024 revenue up 5.9% to $191.2M; adjusted EPS down to $0.96

  Net revenues $191.2M vs $180.6M in Q3 2023, up 5.9%.

• August 30, 2024, 7:59 PM ET other material materiality 0.45 neutral item 1.01

  Amphastar subsidiary enters exclusive Primatene MIST distribution deal for Greater China; est. $10M over 10 yrs

  Armstrong (Amphastar subsidiary) appoints Genreach as exclusive distributor for Primatene MIST in Mainland China, Taiwan, Hong Kong, Macau; 10-year term.

• August 7, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Amphastar Q2 revenue $182.4M, adjusted EPS $0.94; both up ~25-45% YoY

  Net revenues $182.4M (Q2) vs $145.7M YoY; six-month $354.2M vs $285.7M.

• June 4, 2024, 7:59 PM ET other material materiality 0.40 positive item 5.02item 5.07item 8.01item 9.01

  Amphastar board authorizes $50M increase to share buyback program to offset dilution

  $50M increase to buyback program authorized June 3, 2024; program continues indefinitely.

• May 8, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  Amphastar Q1 2024 net revenue $171.8M, GAAP EPS $0.81, adjusted EPS $1.04

  Net revenues of $171.8M vs $140.0M in Q1 2023, up 23% YoY.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.75 · Median 0.60 · Most common event earnings

7 positive 5 negative 9 neutral

source · AMPH on sec.gov